Novartis renews commitment to neglected tropical disease and malaria elimination, investing USD 250 million over five years to research and develop new treatments

Novartis endorses the Kigali Declaration on neglected tropical diseases, pledging USD 250 million to advance R&D of new treatments against NTDs and malaria over five years Commitment includes USD 100 million to advance R&D for Chagas disease, leishmaniasis, dengue and cryptosporidiosis, and USD 150 million for next-generation antimalarials

Related Keywords

United States ,London ,City Of ,United Kingdom ,Kigali ,W09 ,Rwanda ,America ,Isabella Zinck ,Samir Shah ,Parag Mahanti ,Sloan Simpson ,Alina Levchuk ,Nicole Zinsli Somm ,Novartis Institute For Tropical Diseases ,Novartis Institutes For Biomedical Research ,Twitter ,World Health Organization ,Novartis ,Exchange Commission ,Wellcome ,Drugs For Neglected Diseases Initiative ,Kigali Declaration ,Kigali Summit ,Commonwealth Heads ,Neglected Tropical Disease Roadmap ,Vas Narasimhan ,London Declaration ,Malaria Summit ,Novartis Institute ,Tropical Diseases ,Neglected Diseases Initiative ,Novartis Institutes ,Biomedical Research ,Malaria Report ,Ceo ,Infectious Diseases ,Information Technology ,Malaria ,Medical Specialties ,Pharmaceuticals ,Artemisinin ,Clinical Medicine ,Neglected Tropical Diseases ,Nrntds ,